CombiMatrix Bets on Array-Based Prenatal Testing, Affy Clinical Trials Deal to Drive Growth in H2 | GenomeWeb

This article was originally posted on Aug. 10.

CombiMatrix is anticipating greater revenue growth in coming quarters due to a recent National Institute of Health-funded study that the company expects will accelerate the transition of prenatal testing to arrays from older technologies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.